ArticleRespiratory research2026
Development and external validation of an interpretable machine-learning model for HFpEF comorbidity risk in COPD patients.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and external validation of an explainable machine learning model for in-hospital mortality risk stratification in intensive care unit patients with heart failure.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundChronic Obstructive Pulmonary Disease (COPD) and Heart Failure with preserved Ejection Fraction (HFpEF) frequently coexist, leading to increased hospitalization, mortality, and healthcare burden. Early identification of HFpEF risk in COPD patients is critical for timely intervention.
aimTo develop and validate an interpretable machine learning (ML) model for predicting HFpEF risk in COPD patients and to identify key predictors using explainable artificial intelligence techniques.
methodsThis retrospective study analyzed 1,550 COPD patients, divided into COPD-only and COPD-HFpEF groups. Feature selection was performed using LASSO regression, logistic regression, and Boruta random forest. Ten ML models were developed and evaluated on an internal test set, with the best model further validated on an external cohort (n = 69). Model interpretability was assessed using SHapley Additive exPlanations (SHAP).
resultsNine predictors were consistently selected: NT-proBNP, red blood cell count, fibrinogen, cholesterol, arterial PaO₂, inspiratory capacity (IC), IC% predicted, late diastolic mitral inflow velocity (A wave), and CAT score. The XGBoost model achieved the best performance, with an AUC of 0.898 (95% CI: 0.867-0.929) on the internal test set and 0.819 (95%CI: 0.713 - 0.924) on external validation. SHAP analysis identified NT-proBNP as the most influential predictor.
conclusionThe developed XGBoost model accurately predicts HFpEF risk in COPD patients and offers clinically interpretable insights into key predictive markers, supporting early identification and stratified management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.